🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 121 of 151

  1. Study evaluating the Safety and Efficacy of Etentamig (ABBV-383) in Subjects with Light Chain Amyloidosis

    AbbVie Deutschland GmbH & Co. KG

    Light Chain Amyloidosis

    phase 2 other active

    1 trial

  2. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  3. Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer

    Talion

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  4. Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept

    Regeneron UK Limited

    Thyroid Eye Disease

    phase 2 small molecule completed

    1 trial

  5. Subcutaneous injection of TAK-850

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  6. Sublingual film containing Dexmedetomidine

    BioXcel Therapeutics

    Agitation,Psychomotor

    phase 2 small molecule completed

    1 trial

  7. Suboxone Remote Observed Dosing

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 other completed

    1 trial

  8. Subtyping Primary Aldosteronism with Para-chloro-2-[18F]fluoroethyl-etomidate ([18F]CETO)

    Disc Medicine

    Primary aldosteronism

    phase 2 other active

    1 trial

  9. Sucrose octaacetate [NF], SODIUM CHLORIDE, METHYLPREDNISOLONE VIATRIS 1 g, poudre pour solution injectable (I.V.), LIQUID PREDNISONE

    Pari Pharma GmbH

    IDIOPATHIC PULMONARY FIBROSIS

    phase 2 small molecule active

    1 trial

  10. Sugammadex Injection 2mg/kg

    BRIGHT MINDS BIOSCIENCES INC.

    Anesthesia, General

    phase 2 small molecule completed

    1 trial

  11. Sunvozertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Sunvozertinib, Sunvozertinib

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. Surabgene Lomparvovec (ABBV-RGX-314), Surabgene Lomparvovec (ABBV-RGX-314)

    AbbVie Deutschland GmbH & Co. KG

    Neovascular age-related macular degeneration

    phase 2 small molecule active

    1 trial

  14. Surgery

    Ultragenyx UK Limited

    Spastic Diplegia

    phase 2 other active

    1 trial

  15. Surufatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  16. Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine

    Sun Yat-sen University

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  17. Surzebiclimab

    BeiGene

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  18. Surzebiclimab

    BEONE MEDICINES AUS PTY LTD

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  19. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    chronic limb-threatening ischemia, diabetic foot ulcers

    phase 2 small molecule active

    1 trial

  20. Sustanon 250, solution injectable

    The George Institute

    Androgen deficiency, palliative care

    phase 2 small molecule active

    1 trial

  21. Sutacimig

    Hemab Therapeutics Holdings

    Congenital Factor VII Deficiency

    phase 2 small molecule active

    1 trial

  22. Sutent®/Sunitinib

    United Therapeutics Europe Ltd

    Neurofibromatosis

    phase 2 small molecule terminated

    1 trial

  23. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  24. Systemic chemotherapy (FOLFIRI)

    The First People's Hospital of Lianyungang

    Rectum Cancer

    phase 2 small molecule completed

    1 trial

  25. TACE and HAIC Combined With Regorafenib

    The First People's Hospital of Lianyungang

    Liver Metastasis Colon Cancer

    phase 2 other completed

    1 trial

  26. TACE with adebrelimab and bevacizumab

    The First People's Hospital of Lianyungang

    Adebrelimab

    phase 2 small molecule active

    1 trial

  27. TACHIPIRINA 500 mg compresse, OKi 80 mg granulato per soluzione orale, KLS-GABA 40mg-17mg, KLS-GABA 80mg-34mg

    Dompe' Farmaceutici S.p.A.

    Chronic low back pain

    phase 2 small molecule active

    1 trial

  28. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  29. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Tepotinib

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial

  30. TAK-007

    Takeda

    Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

    phase 2 mab active

    1 trial

  31. TAK-018

    Takeda

    Crohn Disease

    phase 2 small molecule terminated

    1 trial

  32. TAK-019

    Takeda

    Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

    phase 2 mab completed

    1 trial

  33. TAK-041

    NEUROCRINE BIOSCIENCES INC

    Stable Schizophrenia

    phase 2 small molecule completed

    1 trial

  34. TAK-062

    Takeda

    Celiac Disease

    phase 2 small molecule completed

    1 trial

  35. TAK-063 20 mg

    Takeda

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  36. TAK-071

    Takeda

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  37. TAK-079

    Takeda

    Myasthenia Gravis

    phase 2 small molecule completed

    1 trial

  38. TAK-128

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule terminated

    2 trials

  39. TAK-186

    Takeda

    Squamous Cell Cancer of Head and Neck (SCCHN)

    phase 2 small molecule terminated

    1 trial

  40. TAK-188

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  41. TAK-226

    Takeda

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  42. TAK-272

    Takeda

    Type 2 Diabetes Mellitus and Microalbuminuria

    phase 2 small molecule completed

    1 trial

  43. TAK-279

    Takeda

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  44. TAK-279

    Takeda

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  45. TAK-279 Placebo (same excipient as TAK-279), ZASOCITINIB

    Takeda

    Moderate to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  46. TAK-279 placebo (same excipient as TAK-279), ZASOCITINIB, ZASOCITINIB

    Takeda

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  47. TAK-280

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  48. TAK-280, SILTUXIMAB, TOCILIZUMAB, TOCILIZUMAB, SILTUXIMAB, TOCILIZUMAB

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.